Mariela Blum Murphy, M.D.

Peer-Reviewed Articles

1. Weng J, Ajani JA, Murphy MB, Badgwell BD, Tchakarov AS, Mamlouk O, Das P. Immunotherapy Recall: Chemoradiation-Induced Reactivation of Immune Checkpoint Inhibitor Nephritis. JCO Precis Oncol 6:e2200049, 2022. PMID: 35952321.
2. Nelson BE, Ejezie CL, Stephen BA, Nardo M, Campbell E, Gong J, Hong DS, Fu S, Yap TA, Murphy MB, Piha-Paul S, Daver NG, Rojas-Hernandez CM, Naing A. Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience. J Hematol 11(3):113-120, 2022. e-Pub 2022. PMID: 35837373.
3. Seervai RNH, Heberton M, Cho WC, Gill P, Murphy MB, Aung PP, Nagarajan P, Torres-Cabala CA, Patel AB, Ruiz-Bañobre J, Om A, Yamamoto T, Nikolaou V, Curry JL. Severe de novo pustular psoriasiform immune-related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinoma. J Cutan Pathol 49(5):472-481, 2022. e-Pub 2021. PMID: 34888886.
4. Bostock IC, Zhou N, Antonoff MB, Murphy MB, Lin S, Maru D, Mehran R, Rajaram R, Rice D, Sepesi B, Swisher S, Vaporciyan A, Walsh G, Hofstetter W. Prolonged neutrophilia is associated with worse outcomes after Esophagectomy. Dis Esophagus 35(4), 2022. PMID: 34897440.
5. Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Ostoich SA, Kim HR, Ueno M, Mansoor W, Yang WC, Liu T, Bridgewater J, Makino T, Xynos I, Liu X, Lei M, Kondo K, Patel A, Gricar J, Chau I, Kitagawa Y, CheckMate 648 Trial Investigators. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med 386(5):449-462, 2022. PMID: 35108470.
6. Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, Kim YM, Lisyanskaya A, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin EA, Takahashi S, Ramone D, Pikiel J, Mackowiak-Matejczyk B, Guerra Alía EM, Colombo N, Makarova Y, Rischin D, Lheureux S, Hasegawa K, Fujiwara K, Li J, Jamil S, Jankovic V, Chen CI, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Mathias M, Fury MG, Oaknin A, Investigators for GOG Protocol 3016 and ENGOT Protocol En-Cx9. Survival with Cemiplimab in Recurrent Cervical Cancer. N Engl J Med 386(6):544-555, 2022. PMID: 35139273.
7. Serrano M, Araujo JM, Pacheco C, Macetas J, Blum MA, Carrato A, Ruiz E, Berrospi F, Luque C, Chavez I, Payet E, Taxa L, Montenegro P. Adjuvant chemotherapy after curative D2 gastrectomy in Latin American patients with gastric cancer. Ecancermedicalscience 16:1387, 2022. e-Pub 2022. PMID: 35919233.
8. Davis CH, Ikoma N, Mansfield PF, Das P, Minsky BD, Blum MA, Ajani JA, Bass BL, Badgwell BD. Comparison of laparoscopy versus mini-laparotomy for jejunostomy placement in patients with gastric adenocarcinoma. Surg Endosc 35(12):6577-6582, 2021. e-Pub 2020. PMID: 33170336.
9. Erstad DJ, Blum M, Estrella JS, Das P, Minsky BD, Ajani JA, Mansfield PF, Ikoma N, Badgwell BD. Benchmarks for nodal yield and ratio for node-positive gastric cancer. Surgery 170(4):1231-1239, 2021. e-Pub 2021. PMID: 34059344.
10. Allen CJ, Pointer DT, Blumenthaler AN, Mehta RJ, Hoffe SE, Minsky BD, Smith GL, Blum M, Mansfield PF, Ikoma N, Das P, Ajani J, Dineen SP, Fleming JB, Badgwell BD, Pimiento JM. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-institutional Analysis. Ann Surg 274(4):544-548, 2021. PMID: 34132693.
11. Erstad DJ, Blum M, Estrella JS, Das P, Minsky BD, Ajani JA, Mansfield PF, Badgwell BD, Ikoma N. Determinants of Survival for Patients with Neoadjuvant-Treated Node-Negative Gastric Cancer. Ann Surg Oncol 28(11):6638-6648, 2021. e-Pub 2021. PMID: 33754224.
12. Blumenthaler AN, Newhook TE, Ikoma N, Estrella JS, Blum Murphy M, Das P, Minsky BD, Ajani JA, Mansfield PF, Badgwell BD. Concurrent lymphovascular and perineural invasion after preoperative therapy for gastric adenocarcinoma is associated with decreased survival. J Surg Oncol 123(4):911-922, 2021. e-Pub 2021. PMID: 33400838.
13. Allen CJ, Blumenthaler AN, Smith GL, Das P, Minsky BD, Blum M, Ajani J, Mansfield PF, Ikoma N, Badgwell BD. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Preoperative Therapy for Resectable Gastric Adenocarcinoma: A Propensity Score-Matched Analysis of a Large, Single-Institution Experience. Ann Surg Oncol 28(2):758-765, 2021. e-Pub 2020. PMID: 32696305.
14. Wang R, Dang M, Harada K, Han G, Wang F, Pool Pizzi M, Zhao M, Tatlonghari G, Zhang S, Hao D, Lu Y, Zhao S, Badgwell BD, Blum Murphy M, Shanbhag N, Estrella JS, Roy-Chowdhuri S, Abdelhakeem AAF, Wang Y, Peng G, Hanash S, Calin GA, Song X, Chu Y, Zhang J, Li M, Chen K, Lazar AJ, Futreal A, Song S, Ajani JA, Wang L. Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nat Med 27(1):141-151, 2021. e-Pub 2021. PMID: 33398161.
15. Abdelhakeem AA, Wang X, Waters RE, Patnana M, Estrella JS, Blum Murphy M, Trail AM, Lu Y, Devine CE, Ikoma N, Das P, Badgwell BD, Rogers JE, Ajani JA. Preoperatively Treated Diffuse-Type Gastric Adenocarcinoma: Glucose vs. Other Energy Sources Substantially Influence Prognosis and Therapy Response. Cancers (Basel) 13(3), 2021. e-Pub 2021. PMID: 33498613.
16. Badgwell B, Ikoma N, Murphy MB, Wang X, Estrella J, Roy-Chowdhuri S, Das P, Minsky BD, Lano E, Song S, Mansfield P, Ajani J. A Phase II Trial of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Perfusion with Chemotherapy for Patients with Gastric Cancer and Carcinomatosis or Positive Cytology. Ann Surg Oncol 28(1):258-264, 2021. e-Pub 2020. PMID: 32556731.
17. Abdelhakeem A, Patnana M, Wang X, Rogers JE, Murphy MB, Sagebiel T, Ikoma N, Badgwell BD, Trail A, Estrella JS, Lu Y, Devine C, Ajani JA. Influence of Baseline Positron Emission Tomography in Metastatic Gastroesophageal Cancer on Survival and Response to Therapy. Oncology 99(10):659-664, 2021. e-Pub 2021. PMID: 34352788.
18. Blumenthaler AN, Allen CJ, Ikoma N, Blum M, Das P, Minsky BD, Mansfield PF, Ajani JA, Badgwell BD. Laparoscopic HIPEC for Low-Volume Peritoneal Metastasis in Gastric and Gastroesophageal Adenocarcinoma. Ann Surg Oncol 27(13):5047-5056, 2020. e-Pub 2020. PMID: 32737700.
19. Blumenthaler AN, Ikoma N, Blum M, Das P, Minsky BD, Mansfield PF, Ajani JA, Badgwell BD. Relationship between initial management strategy and survival in patients with gastric outlet obstruction due to gastric cancer. J Surg Oncol 122(7):1373-1382, 2020. e-Pub 2020. PMID: 32810292.
20. White MG, Kothari A, Ikoma N, Murphy MB, Song S, Ajani J, Mansfield P, Badgwell B. Factors Associated with Resection and Survival After Laparoscopic HIPEC for Peritoneal Gastric Cancer Metastasis. Ann Surg Oncol 27(13):4963-4969, 2020. e-Pub 2020. PMID: 32648181.
21. Kim BJ, Chiang YJ, Das P, Minsky BD, Blum MA, Ajani JA, Estrella JS, Hofstetter WL, Tzeng CD, Badgwell BD, Mansfield PF, Ikoma N. Treatment Patterns for Gastroesophageal Junction Adenocarcinoma in the United States. J Clin Med 9(11), 2020. e-Pub 2020. PMID: 33138060.
22. Harada K, Patnana M, Wang X, Iwatsuki M, Murphy MAB, Zhao M, Das P, Minsky BD, Weston B, Lee JH, Bhutani MS, Estrella JS, Shanbhag N, Ikoma N, Badgwell BD, Ajani JA. Low metabolic activity in primary gastric adenocarcinoma is associated with resistance to chemoradiation and the presence of signet ring cells. Surg Today 50(10):1223-1231, 2020. e-Pub 2020. PMID: 32409870.
23. Stark AP, Blum MM, Chiang YJ, Das P, Minsky BD, Estrella JS, Ajani JA, Badgwell BD, Mansfield P, Ikoma N. Preoperative Therapy Regimen Influences the Incidence and Implication of Nodal Downstaging in Patients with Gastric Cancer. J Gastric Cancer 20(3):313-327, 2020. e-Pub 2020. PMID: 33024587.
24. Harada K, Hwang H, Wang X, Abdelhakeem A, Iwatsuki M, Murphy MAB, Maru DM, Weston B, Lee JH, Rogers JE, Trail A, Shanbhag N, Zhao M, Bhutani MS, Nguyen QN, Swisher SG, Ikoma N, Das P, Hofstetter WL, Badgwell BD, Ajani JA. Brain metastases in patients with upper gastrointestinal cancer is associated with proximally located adenocarcinoma and lymph node metastases. Gastric Cancer 23(5):904-912, 2020. e-Pub 2020. PMID: 32347396.
25. Deng W, Jethwa KR, Gonuguntla K, Liao Z, Yoon HH, Murphy MB, Haddock MG, Hallemeier CL, Lin SH. Multi-institutional Evaluation of Curative Intent Chemoradiotherapy for Patients With Clinical T1N0 Esophageal Adenocarcinoma. Adv Radiat Oncol 5(5):951-958, 2020. e-Pub 2020. PMID: 33083658.
26. Zafar SN, Blum M, Chiang YJ, Ajani JA, Estrella JS, Das P, Minsky BD, Hofstetter WL, Mansfield P, Badgwell BD, Ikoma N. Preoperative Chemoradiation Versus Chemotherapy in Gastroesophageal Junction Adenocarcinoma. Ann Thorac Surg 110(2):398-405, 2020. e-Pub 2020. PMID: 32289300.
27. Moningi S, Ajani JA, Badgwell BD, Murphy MB, Ikoma N, Mansfield PF, Ho JC, Suh Y, Crane C, Herman JM, Holliday EB, Koay E, Koong AC, Krishnan S, Minsky B, Smith G, Taniguchi C, Das P. IMRT Reduces Acute Toxicity in Patients Treated With Preoperative Chemoradiation for Gastric Cancer. Adv Radiat Oncol 5(3):369-376, 2020. e-Pub 2019. PMID: 32529130.
28. Allen CJ, Vreeland TJ, Newhook TE, Das P, Minsky BD, Blum M, Ajani J, Ikoma N, Mansfield PF, Badgwell BD. Prognostic Value of Lymph Node Yield After Neoadjuvant Chemoradiation for Gastric Cancer. Ann Surg Oncol 27(2):534-542, 2020. e-Pub 2019. PMID: 31552618.
29. Allen CJ, Blumenthaler AN, Das P, Minsky BD, Blum M, Roy-Chowdhuri S, Ajani JA, Ikoma N, Mansfield PF, Badgwell BD. Staging laparoscopy and peritoneal cytology in patients with early stage gastric adenocarcinoma. World J Surg Oncol 18(1):39, 2020. e-Pub 2020. PMID: 32066454.
30. Veeranki OL, Tong Z, Mejia A, Verma A, Katkhuda R, Bassett R, Kim TB, Wang J, Lang W, Mino B, Solis L, Kingsley C, Norton W, Tailor R, Wu JY, Krishnan S, Lin SH, Blum M, Hofstetter W, Ajani J, Kopetz S, Maru D. A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries. Dis Model Mech 12(12), 2019. e-Pub 2019. PMID: 31732509.
31. Allen CJ, Newhook TE, Vreeland TJ, Das P, Minsky BD, Blum M, Song S, Ajani J, Ikoma N, Mansfield PF, Roy-Chowdhuri S, Badgwell BD. Yield of peritoneal cytology in staging patients with gastric and gastroesophageal cancer. J Surg Oncol 120(8):1350-1357, 2019. e-Pub 2019. PMID: 31612494.
32. Nelson DB, Mitchell KG, Weston BR, Betancourt S, Maru D, Rice DC, Mehran RJ, Sepesi B, Antonoff MB, Walsh GL, Swisher SG, Roth JA, Vaporciyan AA, Blum M, Hofstetter WL. Should endoscopic mucosal resection be attempted for cT2N0 esophageal cancer?. Dis Esophagus 32(10):1-6, 2019. PMID: 30888418.
33. Stark AP, Ikoma N, Chiang YJ, Estrella JS, Das P, Minsky BD, Blum MM, Ajani JA, Mansfield P, Badgwell BD. Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy. Ann Surg Oncol 26(11):3602-3610, 2019. e-Pub 2019. PMID: 31350645.
34. Mitchell KG, Ikoma N, Nelson DB, Maru DM, Erasmus JJ, Weston BR, Vaporciyan AA, Antonoff MB, Mehran RJ, Rice DC, Roth JA, Swisher SG, Sepesi B, Walsh GL, Correa AM, Das P, Blum MA, Badgwell BD, Hofstetter WL. Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma. Ann Thorac Surg 108(3):845-851, 2019. e-Pub 2019. PMID: 31102632.
35. Veeranki OL, Tong Z, Dokey R, Mejia A, Zhang J, Qiao Y, Singh PK, Katkhuda R, Mino B, Tailor R, Canales JR, Bassett R, Ajani J, Wu JY, Kopetz S, Blum M, Hofstetter W, Tetzlaff M, Krishnan S, Lin SH, Maru D. Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma. Oncotarget 10(45):4703-4718, 2019. e-Pub 2019. PMID: 31384397.
36. Newhook TE, Agnes A, Blum M, Estrella JS, Das P, Ho L, Ajani JA, Minsky BD, Mansfield P, Badgwell BD. Laparoscopic Hyperthermic Intraperitoneal Chemotherapy is Safe for Patients with Peritoneal Metastases from Gastric Cancer and May Lead to Gastrectomy. Ann Surg Oncol 26(5):1394-1400, 2019. e-Pub 2019. PMID: 30680477.
37. Tong Z, Mejia A, Veeranki O, Verma A, Correa AM, Dokey R, Patel V, Solis LM, Mino B, Kathkuda R, Rodriguez-Canales J, Lin SH, Krishnan S, Kopetz S, Blum M, Ajani JA, Hofstetter WL, Maru DM. Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma. Ther Adv Med Oncol 11:1758835919864850, 2019. e-Pub 2019. PMID: 31384313.
38. Dumbrava EEI, Balaji K, Raghav K, Hess K, Javle M, Blum-Murphy M, Ajani J, Kopetz S, Broaddus R, Routbort M, Demirhan M, Zheng X, Pant S, Tsimberidou AM, Subbiah V, Hong DS, Rodon J, Shaw KM, Piha-Paul SA, Meric-Bernstam F. Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 32923865.
39. Ikoma N, Estrella JS, Blum M, Das P, Chen HC, Wang X, Fournier K, Mansfield P, Ajani J, Badgwell BD. Central Lymph Node Metastasis in Gastric Cancer Is Predictive of Survival After Preoperative Therapy. J Gastrointest Surg 22(8):1325-1333, 2018. e-Pub 2018. PMID: 29679346.
40. Xi M, Hallemeier CL, Merrell KW, Liao Z, Murphy MAB, Ho L, Hofstetter WL, Mehran R, Lee JH, Bhutani MS, Weston B, Maru DM, Komaki R, Ajani JA, Lin SH. Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma. Ann Surg 268(2):289-295, 2018. PMID: 28628563.
41. Shimodaira Y, Slack RS, Harada K, Chen HC, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Blum MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Mares J, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA. Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial. Br J Cancer 118(3):331-337, 2018. e-Pub 2017. PMID: 29235564.
42. Badgwell B, Blum M, Das P, Estrella J, Wang X, Fournier K, Royal R, Mansfield P, Ajani J. Lessons learned from a phase II clinical trial of laparoscopic HIPEC for gastric cancer. Surg Endosc 32(1):512, 2018. e-Pub 2017. PMID: 28643069.
43. Ikoma N, Blum M, Estrella JS, Das P, Hofstetter WL, Fournier KF, Mansfield P, Ajani JA, Badgwell BD. Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy. Gastric Cancer 21(1):74-83, 2018. e-Pub 2017. PMID: 28643144.
44. Ikoma N, Lee JH, Bhutani MS, Ross WA, Weston B, Chiang YJ, Blum MA, Sagebiel T, Devine CE, Matamoros A, Fournier K, Mansfield P, Ajani JA, Badgwell BD. Preoperative accuracy of gastric cancer staging in patient selection for preoperative therapy: race may affect accuracy of endoscopic ultrasonography. J Gastrointest Oncol 8(6):1009-1017, 2017. PMID: 29299361.
45. Ikoma N, Das P, Blum M, Estrella JS, Devine CE, Wang X, Fournier K, Mansfield P, Minsky BD, Ajani J, Badgwell BD. Preoperative Chemoradiation Therapy Does Not Increase Risk of Anastomotic Leak in Patients With Gastric Cancer. Int J Radiat Oncol Biol Phys 99(3):660-666, 2017. e-Pub 2017. PMID: 29280460.
46. Xi M, Xu C, Liao Z, Chang JY, Gomez DR, Jeter M, Cox JD, Komaki R, Mehran R, Blum MA, Hofstetter WL, Maru DM, Bhutani MS, Lee JH, Weston B, Ajani JA, Lin SH. Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. Int J Radiat Oncol Biol Phys 99(3):667-676, 2017. e-Pub 2017. PMID: 29280461.
47. Shimodaira Y, Slack RS, Harada K, Bhutani MS, Elimova E, Staerkel GA, Sneige N, Erasmus J, Shiozaki H, Charalampakis N, Planjery V, Kaya DM, Amlashi FG, Blum MA, Skinner HD, Minsky BD, Maru DM, Hofstetter WL, Swisher SG, Mares JE, Rogers JE, Lin QD, Ross WA, Weston B, Lee JH, Ajani JA. Utility of endoscopic ultrasound-guided fine-needle aspiration of regional lymph nodes that are proximal to and far from the primary distal esophageal carcinoma. Oncotarget 8(45):79356-79365, 2017. e-Pub 2017. PMID: 29108314.
48. Atay SM, Blum M, Sepesi B. Adjuvant chemotherapy following trimodality therapy for esophageal carcinoma-Is the evidence sufficient?. J Thorac Dis 9(10):3626-3629, 2017. PMID: 29268359.
49. Elimova E, Slack RS, Chen HC, Planjery V, Shiozaki H, Shimodaira Y, Charalampakis N, Lin Q, Harada K, Wadhwa R, Estrella JS, Kaya DM, Sagebiel T, Lee JH, Weston B, Bhutani M, Murphy MB, Matamoros A, Minsky B, Das P, Mansfield PF, Badgwell BD, Ajani JA. Patterns of relapse in patients with localized gastric adenocarcinoma who had surgery with or without adjunctive therapy: costs and effectiveness of surveillance. Oncotarget 8(46):81430-81440, 2017. e-Pub 2017. PMID: 29113402.
50. Ikoma N, Chen HC, Wang X, Blum M, Estrella JS, Fournier K, Mansfield P, Ajani J, Badgwell BD. Patterns of Initial Recurrence in Gastric Adenocarcinoma in the Era of Preoperative Therapy. Ann Surg Oncol 24(9):2679-2687, 2017. e-Pub 2017. PMID: 28332034.
51. Shi A, Liao Z, Allen PK, Ho L, Murphy MB, Maru DM, Swisher SG, Hofstetter WL, Mehran RJ, Cox JD, Komaki R, Lin SH. Long-term survival and toxicity outcomes of intensity modulated radiation therapy for the treatment of esophageal cancer: A large single-institutional cohort study. Adv Radiat Oncol 2(3):316-324, 2017. e-Pub 2017. PMID: 29114598.
52. Xi M, Liao Z, Deng W, Xu C, Komaki R, Blum M, Hofstetter WL, Ho L, Lin SH. A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer. J Thorac Oncol 12(6):1001-1010, 2017. e-Pub 2017. PMID: 28351804.
53. Lopez A, Mariette X, Bachelez H, Belot A, Bonnotte B, Hachulla E, Lahfa M, Lortholary O, Loulergue P, Paul S, Roblin X, Sibilia J, Blum M, Danese S, Bonovas S, Peyrin-Biroulet L. Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis. J Autoimmun 80:10-27, 2017. e-Pub 2017. PMID: 28381345.
54. Ikoma N, Blum M, Chiang YJ, Estrella JS, Roy-Chowdhuri S, Fournier K, Mansfield P, Ajani J, Badgwell BD. Race Is a Risk for Lymph Node Metastasis in Patients With Gastric Cancer. Ann Surg Oncol 24(4):960-965, 2017. e-Pub 2016. PMID: 27778127.
55. Welsh JW, Seyedin SN, Allen PK, Hofstetter WL, Ajani JA, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Nguyen QN, Minsky BD, Erasmus JJ, Lee JH, Bhutani M, Komaki RU. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. J Thorac Oncol 12(2):375-382, 2017. e-Pub 2016. PMID: 27794500.
56. Elimova E, Janjigian YY, Mulcahy M, Catenacci DV, Blum MA, Almhanna K, Hecht JR, Ajani JA. It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma. J Clin Oncol 35(4):475-477, 2017. e-Pub 2016. PMID: 28129519.
57. Badgwell B, Blum M, Estrella J, Ajani J. Personalised therapy for localised gastric and gastro-oesophageal adenocarcinoma. Lancet Oncol 17(12):1628-1629, 2016. e-Pub 2016. PMID: 27776842.
58. Ikoma N, Blum M, Chiang YJ, Estrella JS, Roy-Chowdhuri S, Fournier K, Mansfield P, Ajani JA, Badgwell BD. Yield of Staging Laparoscopy and Lavage Cytology for Radiologically Occult Peritoneal Carcinomatosis of Gastric Cancer. Ann Surg Oncol 23(13):4332-4337, 2016. e-Pub 2016. PMID: 27384751.
59. Ikoma N, Blum M, Chiang YJ, Estrella JS, Roy-Chowdhuri S, Fournier K, Mansfield P, Ajani JA, Badgwell BD. Survival rates in T1 and T2 gastric cancer: A Western report. J Surg Oncol 114(5):602-606, 2016. e-Pub 2016. PMID: 27439746.
60. Al-Shamsi HO, Fahmawi Y, Dahbour I, Tabash A, Rogers JE, Mares JE, Blum MA, Estrella J, Matamoros A, Sagebiel T, Devine CE, Badgwell BD, Lin QD, Das P, Ajani JA. Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience. J Gastrointest Oncol 7(4):499-505, 2016. PMID: 27563438.
61. Badgwell B, Blum M, Elimova E, Estrella J, Chiang YJ, Das P, Mansfield P, Ajani J. Frequency of Resection After Preoperative Chemotherapy or Chemoradiotherapy for Gastric Adenocarcinoma. Ann Surg Oncol 23(6):1948-55, 2016. e-Pub 2016. PMID: 26868957.
62. Sudo K, Wang X, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Rice DC, Lee JH, Weston B, Bhutani MS, Hiremath A, Charalampakis N, Komaki R, Blum MA, Swisher SG, Maru DM, Skinner HD, Garris JL, Rogers JE, Hofstetter WL, Ajani JA. A Nomogram to Predict Distant Metastases After Multimodality Therapy for Patients With Localized Esophageal Cancer. J Natl Compr Canc Netw 14(2):173-9, 2016. PMID: 26850487.
63. Charalampakis N, Nogueras González GM, Elimova E, Wadhwa R, Shiozaki H, Shimodaira Y, Blum MA, Rogers JE, Harada K, Matamoros A, Sagebiel T, Das P, Minsky BD, Lee JH, Weston B, Bhutani MS, Estrella JS, Badgwell BD, Ajani JA. The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation. Oncology 90(5):239-47, 2016. e-Pub 2016. PMID: 27046280.
64. Elimova E, Wang X, Etchebehere E, Shiozaki H, Shimodaira Y, Wadhwa R, Planjery V, Charalampakis N, Blum MA, Hofstetter W, Lee JH, Weston BR, Bhutani MS, Rogers JE, Maru D, Skinner HD, Macapinlac HA, Ajani JA. 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. Eur J Cancer 51(17):2545-52, 2015. e-Pub 2015. PMID: 26321501.
65. Badgwell B, Blum M, Estrella J, Chiang YJ, Das P, Matamoros A, Fournier K, Mansfield P, Ajani J. Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy. J Am Coll Surg 221(1):83-90, 2015. e-Pub 2015. PMID: 26002780.
66. Badgwell B, Roy-Chowdhuri S, Chiang YJ, Matamoros A, Blum M, Fournier K, Mansfield P, Ajani J. Long-term survival in patients with metastatic gastric and gastroesophageal cancer treated with surgery. J Surg Oncol 111(7):875-81, 2015. e-Pub 2015. PMID: 25872485.
67. Shiozaki H, Slack R, Sudo K, Elimova E, Wadhwa R, Chen HC, Skinner HD, Komaki R, Lee JH, Weston B, Bhutani MS, Blum MA, Rogers JE, Maru DM, Hofstetter WL, Ajani JA. Geographic distribution of regional metastatic nodes affects the outcome of trimodality-eligible patients with esophageal adenocarcinoma. Oncology 88(6):332-6, 2015. e-Pub 2015. PMID: 25765098.
68. Elimova E, Shiozaki H, Wadhwa R, Sudo K, Chen Q, Estrella JS, Blum MA, Badgwell B, Das P, Song S, Ajani JA. Medical management of gastric cancer: A 2014 update. World J Gastroenterol 20(38):13637-13647, 2014. PMID: 25320502.
69. Sudo K, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Taketa T, Blum MA, Lee JH, Bhutani MS, Weston B, Ross WA, Komaki R, Rice DC, Swisher SG, Hofstetter WL, Maru DM, Skinner HD, Ajani JA. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol 32(30):3400-5, 2014. e-Pub 2014. PMID: 25225435.
70. Taketa T, Sudo K, Correa AM, Wadhwa R, Shiozaki H, Elimova E, Campagna MC, Blum MA, Skinner HD, Komaki RU, Lee JH, Bhutani MS, Weston BR, Rice DC, Swisher SG, Maru DM, Hofstetter WL, Ajani JA. Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. J Natl Compr Canc Netw 12(8):1139-44, 2014. PMID: 25099446.
71. Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget 5(7):1837-45, 2014. PMID: 24742823.
72. Wadhwa R, Elimova E, Shiozaki H, Sudo K, Blum MA, Estrella JS, Chen Q, Song S, Ajani JA. Anti-angiogenic agent ramucirumab: meaningful or marginal?. Expert Rev Anticancer Ther 14(4):367-79, 2014. e-Pub 2014. PMID: 24605771.
73. Shiozaki H, Sudo K, Xiao L, Wadhwa R, Elimova E, Hofstetter WL, Skinner HD, Lee JH, Weston B, Bhutani MS, Blum MA, Maru DM, Ajani JA. Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer. Oncology 86(5-6):336-9, 2014. e-Pub 2014. PMID: 24925190.
74. Sudo K, Taketa T, Correa AM, Campagna MC, Wadhwa R, Blum MA, Komaki R, Lee JH, Bhutani MS, Weston B, Skinner HD, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Ajani JA. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol 31(34):4306-10, 2013. e-Pub 2013. PMID: 24145339.
75. Blum MA, Taketa T, Sudo K, Wadhwa R, Skinner HD, Ajani JA. Chemoradiation for esophageal cancer. Thorac Surg Clin 23(4):551-8, 2013. PMID: 24199704.
76. Francis AM, Sepesi B, Correa AM, Blum MA, Erasmus JJ, Lee JH, Maru DM, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Welsh JW, Swisher SG, Hofstetter WL, University of Texas MD Anderson Esophageal Cancer Group. The influence of histopathologic tumor viability on long-term survival and recurrence rates following neoadjuvant therapy for esophageal adenocarcinoma. Ann Surg 258(3):500-7, 2013. PMID: 24022442.
77. Wadhwa R, Taketa T, Sudo K, Blum MA, Ajani JA. Modern oncological approaches to gastric adenocarcinoma. Gastroenterol Clin North Am 42(2):359-69, 2013. e-Pub 2013. PMID: 23639645.
78. Taketa T, Xiao L, Sudo K, Suzuki A, Wadhwa R, Blum MA, Lee JH, Weston B, Bhutani MS, Skinner H, Komaki R, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Ajani JA. Propensity-based matching between esophagogastric cancer patients who had surgery and who declined surgery after preoperative chemoradiation. Oncology 85(2):95-9, 2013. e-Pub 2013. PMID: 23860252.
79. Wadhwa R, Taketa T, Correa AM, Sudo K, Campagna MC, Blum MA, Komaki R, Skinner H, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher S, Hofstetter WL, Ajani JA. Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance. Oncology 85(4):204-7, 2013. e-Pub 2013. PMID: 24051869.
80. Hayashi Y, Xiao L, Suzuki A, Blum MA, Sabloff B, Taketa T, Maru DM, Welsh J, Lin SH, Weston B, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Ajani JA. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with esophageal cancer. Eur J Cancer 48(18):3396-404, 2012. e-Pub 2012. PMID: 22853875.
81. Taketa T, Ohigashi S, Suzuki K, Sudo K, Shiozaki H, Suzuki A, Blum MA, Ajani JA, Onodera H. Paraneoplastic neurological syndromes associated with gastric cancer: a case report and review of the literature. Clin J Gastroenterol 5(5):355-60, 2012. e-Pub 2012. PMID: 26181075.
82. Blum MA, Suzuki A, Taketa T, Ajani JA. Current therapeutic approaches to localized carcinoma of the esophagus and gastroesophageal junction. Clinical Practice Vol 9(No 4):463-471, 2012.
83. Blum MA, Ajani JA. Therapy: Localized gastric cancer-a CLASSIC shift in the paradigm?. Nat Rev Gastroenterol Hepatol 9(4):194-5, 2012. e-Pub 2012. PMID: 22392288.
84. Ajani JA, Blum MA, Estrella JS, Das P, Fournier KF. Gastric Cancer: Apples Will Always Be Apples. J Clin Oncol 30(9):1017-8, 2012. e-Pub 2012. PMID: 22331947.
85. Suzuki A, Xiao L, Hayashi Y, Blum MA, Welsh JW, Lin SH, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Erasmus J, Ajani JA. Nomograms for Prognostication of Outcome in Patients with Esophageal and Gastroesophageal Carcinoma Undergoing Definitive Chemoradiotherapy. Oncology 82(2):108-113, 2012. e-Pub 2012. PMID: 22328056.
86. Blum MA, Hayashi Y, Ajani JA. Advanced gastroesophageal carcinoma: an update on the current therapeutic landscape. Onkologie 35(4):204-9, 2012. e-Pub 2012. PMID: 22488092.
87. Suzuki A, Xiao L, Taketa T, Blum MA, Matamoros A, Chien PL, Mansfield PF, Fournier KF, Weston B, Lee JH, Bhutani MS, Estrella JS, Delclos ME, Krishnan S, Das P, Ajani JA. Localized Gastric Cancer Treated with Chemoradation without Surgery: UTMD Anderson Cancer Center Experience. Oncology 82(6):347-351, 2012. e-Pub 2012. PMID: 22677933.
88. Taketa T, Correa AM, Suzuki A, Blum MA, Chien P, Lee JH, Welsh J, Lin SH, Maru DM, Erasmus JJ, Bhutani MS, Weston B, Rice DC, Vaporciyan AA, Hofstetter WL, Swisher SG, Ajani JA. Outcome of Trimodality-Eligible Esophagogastric Cancer Patients Who Declined Surgery after Preoperative Chemoradiation. Oncology 83(5):300-304, 2012. e-Pub 2012. PMID: 22964903.
89. Blum MA, Suzuki A, Taketa T, Ajani J. The role of S-1 in the treatment of Gastric Cancer. Gastrointestinal Cancer: Targets and Therapy 1(1):59-67, 2011.
90. Blum M, Suzuki A, Ajani JA. A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma. Future Oncol 7(6):715-26, 2011. PMID: 21675835.
91. Blum MA, Takashi T, Suzuki A, Ajani JA. Management of localized gastric cancer. J Surg Oncol. e-Pub 2013. PMID: 23303654.
92. Elimova E, Shiozaki H, Slack RS, Chen HC, Wadhwa R, Sudo K, Charalampakis N, Hiremath A, Estrella JS, Matamoros A, Sagebiel T, Das P, Rogers JE, Garris JL, Blum MA, Badgwell B, Ajani JA. Early versus Delayed Therapy of Advanced Gastric Cancer Patients - Does It Make a Difference?. Oncology. e-Pub 2015. PMID: 26159599.
93. Neishaboori N, Wadhwa R, Nogueras-González GM, Elimova E, Shiozaki H, Sudo K, Charalampakis N, Hiremath A, Lee JH, Bhutani MS, Weston B, Blum MA, Rogers JE, Garris JL, Rice DC, Komaki R, Swisher SG, Skinner HD, Hofstetter WL, Ajani JA. Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation: Its Clinical Implications. Oncology. e-Pub 2015. PMID: 25765719.
94. Amini A, Ajani J, Komaki R, Allen PK, Minsky BD, Blum M, Xiao L, Suzuki A, Hofstetter W, Swisher S, Gomez D, Liao Z, Lee JH, Bhutani MS, Welsh JW. Factors Associated with Local-Regional Failure After Definitive Chemoradiation for Locally Advanced Esophageal Cancer. Ann Surg Oncol. e-Pub 2013. PMID: 24197760.
95. Taketa T, Sudo K, Wadhawa R, Blum MM, Ajani JA. Adjuvant Therapy in Gastric Cancer: What Is The Optimal Approach?. Curr Oncol Rep. e-Pub 2013. PMID: 23355076.
96. Pujara D, Mansfield P, Ajani J, Blum M, Elimova E, Chiang YJ, Das P, Badgwell B. Comprehensive geriatric assessment in patients with gastric and gastroesophageal adenocarcinoma undergoing gastrectomy. J Surg Oncol. e-Pub 2015. PMID: 26482869.
97. Kneuertz PJ, Hofstetter WL, Chiang YJ, Das P, Blum M, Elimova E, Mansfield P, Ajani J, Badgwell B. Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ?. Ann Surg Oncol. e-Pub 2015. PMID: 26564243.
98. Charalampakis N, Xiao L, Elimova E, Wadhwa R, Shiozaki H, Shimodaira Y, Blum MA, Planjery V, Rogers JE, Matamoros A, Sagebiel T, Das P, Lee JH, Bhutani MS, Weston B, Estrella JS, Badgwell BD, Ajani JA. Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively. Oncology. e-Pub 2015. PMID: 26393501.
99. Badgwell B, Ajani J, Blum M, Ho L, Fournier K, Chiang YJ, Matamoros A, Das P, Mansfield P. Postoperative Morbidity and Mortality Rates are Not Increased for Patients with Gastric and Gastroesophageal Cancer Who Undergo Preoperative Chemoradiation Therapy. Ann Surg Oncol. e-Pub 2015. PMID: 26059652.
100. Ikoma N, Agnes A, Chen HC, Wang X, Blum MM, Das P, Minsky B, Estrella JS, Mansfield P, Ajani JA, Badgwell BD. Linitis Plastica: a Distinct Type of Gastric Cancer. J Gastrointest Surg. e-Pub 2019. PMID: 31754987.
101. Bozkurt M, Antonoff M, Jaramillo S, Sagebiel T, Murphy MB. Gastroesophageal Cancer During Pregnancy: a Case Report and Review of the Literature. J Gastrointest Cancer. e-Pub 2018. PMID: 29577180.
102. Thiels CA, Ikoma N, Fournier K, Das P, Blum M, Estrella JS, Minsky BD, Ajani J, Mansfield P, Badgwell BD. Repeat staging laparoscopy for gastric cancer after preoperative therapy. J Surg Oncol. e-Pub 2018. PMID: 29878364.
103. Elimova E, Wang X, Qiao W, Sudo K, Wadhwa R, Shiozaki H, Shimodaira Y, Planjery V, Charalampakis N, Lee JH, Weston BR, Bhutani MS, Komaki R, Rice DC, Swisher SG, Blum MA, Rogers JE, Skinner HD, Maru DM, Hofstetter WL, Ajani JA. Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology 94(6):345-353. e-Pub 2018. PMID: 29705797.
104. Ikoma N, Blum M, Estrella JS, Wang X, Fournier KF, Mansfield PF, Ajani JA, Badgwell BD. Left Gastric Artery Lymph Nodes Should Be Included in D1 Lymph Node Dissection in Gastric Cancer. J Gastrointest Surg. e-Pub 2017. PMID: 28819789.
105. Badgwell B, Blum M, Das P, Estrella J, Wang X, Ho L, Fournier K, Royal R, Mansfield P, Ajani J. Phase II Trial of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal Carcinomatosis or Positive Peritoneal Cytology in Patients with Gastric Adenocarcinoma. Ann Surg Oncol. e-Pub 2017. PMID: 28799004.
106. Yap TA, Gainor JF, Callahan MK, Falchook GS, Pachynski RK, LoRusso P, Kummar S, Gibney GT, Burris HA, Tykodi SS, Rahma OE, Seiwert TY, Papadopoulos KP, Blum Murphy M, Park H, Hanson A, Hashambhoy-Ramsay Y, McGrath L, Hooper E, Xiao X, Cohen H, Fan M, Felitsky D, Hart C, McComb R, Brown K, Sepahi A, Jimenez J, Zhang W, Baeck J, Laken H, Murray R, Trehu E, Harvey CJ. First in Human Phase 1/2 ICONIC Trial of the ICOS agonist vopratelimab alone and with nivolumab: ICOS high CD4 T cell populations and predictors of response. Clin Cancer Res. e-Pub 2022. PMID: 35511938.
107. Zhou N, Hofstetter WL, Esophageal Squamous Cell Carcinoma Working Group, Mitchell KG, Bayley EM, Ajani JA, Antonoff MB, Betancourt SL, Blum-Murphy M, Feldman HA, Lin SH, Maru DM, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Weston BR. Salvage Esophagectomy Definition Influences Comparative Outcomes in Esophageal Squamous Cell Cancers. Ann Thorac Surg. e-Pub 2021. PMID: 34883083.
108. Hao D, He S, Harada K, Pizzi MP, Lu Y, Guan P, Chen L, Wang R, Zhang S, Sewastjanow-Silva M, Abdelhakeem A, Shanbhag N, Bhutani M, Han G, Lee JH, Zhao S, Weston B, Blum Murphy M, Waters R, Estrella JS, Roy-Chowdhuri S, Gan Q, Lee JS, Peng G, Hanash SM, Calin GA, Song X, Zhang J, Song S, Wang L, Ajani JA. Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma. Gut. e-Pub 2020. PMID: 33334899.
109. Chen D, Menon H, Verma V, Seyedin SN, Ajani JA, Hofstetter WL, Nguyen QN, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Barsoumian HB, Erasmus JJ, Lee JH, Bhutani MS, Hess KR, Minsky BD, Welsh JW. Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. JAMA Oncol. e-Pub 2019. PMID: 31529018.
110. Abu-Sbeih H, Szafron D, Elkafrawy AA, Garcia-Rodriguez V, Ma W, Xu A, Khurana S, Numan L, Chen E, Goldstein R, Tsen A, Peng Y, Blum M, Kopetz ES, Ikoma N, Shatila M, Qiao W, Raju GS, Ross WA, Ge PS, Coronel E, Wang Y. Endoscopy for the diagnosis and treatment of gastrointestinal bleeding caused by malignancy. J Gastroenterol Hepatol. e-Pub 2022. PMID: 35730192.
111. Erstad DJ, Blum M, Estrella JS, Das P, Minsky BD, Ajani JA, Mansfield PF, Ikoma N, Badgwell BD. Navigating Nodal Metrics for Node-Positive Gastric Cancer in the United States: An NCDB-Based Study and Validation of AJCC Guidelines. J Natl Compr Canc Netw:1-12. e-Pub 2021. PMID: 34678759.

Editorials

1. Blum Murphy M, Taketa T, Sudo K, Lee JH, Ajani JA. Surveillance for esophageal cancer: does it make sense?. J Natl Compr Canc Netw 10(12):1590-92, 2012. PMID: 23221793.
2. Blum MA, Ajani JA. Chemoradiation: Gastro-oesophageal cancer-is CROSSing over so hard to do?. Nat Rev Clin Oncol 9(9):493-4, 2012. PMID: 22825372.
3. Blum Murphy MA, Taketa T, Sudo K, Lee JH, Ajani JA. Surveillance for esophageal cancer: does it make sense?. J Natl Compr Canc Netw 10:1590-92, 2012.
4. Blum MA, Ajani JA. Many a mickle makes a muckle. Translating a gastric cancer phenotype into a bigger thing. Onkologie 34(10):499-500, 2011. PMID: 21985847.

Abstracts

1. Brian D. Badgwell, Mariela A. Blum, Prajnan Das, Elena Elimova, Paul F. Mansfield, Jaffer A. Ajani. A phase II study of laparoscopic hyperthermic intraperitoneal chemoperfusion (HIPEC) for gastric carcinomatosis or positive cytology. 2016 Gastrointestinal Cancers Symposium, 2016.
2. Elena Elimova, Soo-Mi Kim, Xuemei Wang, Yusuke Shimodaira, Bo Hwa Sohn, Heath Devin Skinner, Jeffrey H. Lee, Brian Weston, Manoop S. Bhutani, Bruce D. Minsky, David C. Rice, Jun Eul Hwang, Stephen Swisher, Wayne Lewis Hofstetter, Mariela A. Blum, Dipen M. Maru, Jaffer A. Ajani, Ju-Seog Lee; The University of Texas MD Anderson Cancer Center, Houston, TX; Jeonbuk National University Medical School and Hospital, Jeonju, North Korea; Departments of Systems Biology, Houston, TX; The University of Chicago Medical Center, Chicago, IL. Correlation of pretreatment p63-positive subtype of gastroesophageal adenocarcinoma (GEAC) with pathologic complete response (pathCR) in patients receiving preoperative chemoradiation. 2016 Gastrointestinal Cancers Symposium, 2016.
3. Nikolaos Charalampakis, Lianchun Xiao, Elena Elimova, Yusuke Shimodaira, Hironori Shiozaki, Prajnan Das, Aurelio Matamoros, Tara L. Sagebiel, Mariela A. Blum, Jeffrey H. Lee, Manoop S. Bhutani, Brian Weston, Paul F. Mansfield, Bruce D. Minsky, Brian D. Badgwell, Jaffer A. Ajani. Course and predictors of postoperative outcomes in older patients with localized localized gastric adenocarcinoma treated preoperatively. 2016 Gastrointestinal Cancers Symposium, 2016.
4. Naruhiko Ikoma, Elena Elimova, Mariela A. Blum, Jaffer A. Ajani, Y. Sabrina Chiang, Keith F. Fournier, Paul F. Mansfield, Brian D. Badgwell; The University of Texas MD Anderson Cancer Center, Houston, TX. Preoperative accuracy of gastric cancer staging in patient selection for neoadjuvant therapy. 2016 Gastrointestinal Cancers Symposium, 2016.
5. Naruhiko Ikoma, Elena Elimova, Mariela A. Blum, Jaffer A. Ajani, Y. Sabrina Chiang, Keith F. Fournier, Paul F. Mansfield, Brian D. Badgwell; The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas MD Anderson Cancer Center. Risk Factors for Survival in Early T Stage Gastric Cancer. 2016 Gastrointestinal Cancers Symposium, 2016.
6. Naruhiko Ikoma, Elena Elimova, Mariela A. Blum, Jaffer A. Ajani, Y. Sabrina Chiang, Keith F. Fournier, Paul F. Mansfield, Brian D. Badgwell; The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas MD Anderson Cancer Center, Missouri City, TX. Staging Laparoscopy with Cytology Analysis in Gastric Cancer. 2016 Gastrointestinal Cancers Symposium, 2016.
7. Humaid Obaid Al-Shamsi, Jane Rogers, Jeannette Elizabeth Mares, Mariela A. Blum, Ibrahim Dahbour, Yazan Fahmawi, Quan Lin, Jaffer A. Ajani; The University of Texas MD Anderson Cancer Center, Houston, TX. Continuation of trastuzumab beyond disease progression in patient with metastatic gastric cancer: A retrospective analysis of 25 cases- The MD Anderson experience. 2016 ASCO Annual Meeting, 2016.
8. Yusuke Shimodaira, Rebecca Slack, Hsiang-Chun Chen, Manoop S. Bhutani, Jeffrey H Lee, Brian Weston, Elena Elimova, Quan Lin, Kazuto Harada, Fatemeh G Amlashi, Dilsa Mizrak, Mariela A. Blum, Jack A. Roth, Stephen Swisher, Heath Devin Skinner, Wayne Lewis Hofstetter, Ritsuko Komaki, Garrett L. Walsh, Jaffer A. Ajani; The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas MD Anderson Cancer Center Department of Gastrointestinal Medical Oncology, Houston, TX; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Influence of induction chemotherapy (IC) in trimodality-eligible esophageal cancer patients: Secondary analysis of a randomized trial. 2016 ASCO Annual Meeting, 2016.
9. Mariela A. Blum, Lianchun Xiao, Arlene M. Correa, Roopma Wadhwa, Elena Elimova, Heath Devin Skinner, Ritsuko Komaki, Jeffrey H. Lee, Manoop S. Bhutani, Brian Weston, Zhongxing X. Liao, David C. Rice, Stephen Swisher, Wayne Lewis Hofstetter, Jaffer A. Ajani. Analysis of patients with esophageal cancer following trimodality therapy: Pathological complete remission (PathCR) versus non-PathCR. 2015 ASCO Annual Meeting, 2015.
10. Elena Elimova, Xuemei Wang, Wei Qiao, Kazuki Sudo, Roopma Wadhwa, Hironori Shiozaki, Venkatram Planjery, Nikolaos Charalampakis, Heath Devin Skinner, Jeffrey H. Lee, Brian Weston, Manoop S. Bhutani, Ritsuko Komaki, David C. Rice, Stephen Swisher, Mariela A. Blum, Dipen M. Maru, Wayne Lewis Hofstetter, Jaffer A. Ajani; The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX. Actionable locoregional failures (LRFs) after therapy of localized esophageal carcinoma (LEC): Surveillance strategies and their benefits. 2015 Gastrointestinal Cancers Symposium, 2015.
11. Hironori Shiozaki, Elena Elimova, Rebecca Slack, Hsiang-Chun Chen, Gregg A Staerkel, Nour Sneige, Venkatram Planjery, Nikolaos Charalampakis, Roopma Wadhwa, Kazuki Sudo, Aurelio Matamoros, Jeffrey H. Lee, Brian Weston, Manoop S. Bhutani, Mariela A. Blum, Jeannelyn Estrella, Prajnan Das, Paul F. Mansfield, Brian D. Badgwell, Jaffer A. Ajani; The University of Texas MD Anderson Cancer Center, Houston, TX; Houston Methodist Hospital, Houston, TX. Prognosis of gastric cancer (GC) patients with positive peritoneal cytology. 2015 Gastrointestinal Cancers Symposium, 2015.
12. Yusuke Shimodaira, Elena Elimova, Hironori Shiozaki, Roopma Wadhwa, Nikolaos Charalampakis, Venkatram Planjery, Mariela A. Blum, Quynh Nguyen, Heath Devin Skinner, Rebecca Slack, Dipen M. Maru, Wayne Lewis Hofstetter, Brian Weston, Manoop S. Bhutani, Jeffrey H. Lee, Jaffer A. Ajani; The University of Texas MD Anderson Cancer Center, Houston, TX. Accuracy of EUS-FNA for distant regional lymph nodes in the initial staging of esophageal cancer (EC). 2015 ASCO Annual Meeting, 2015.
13. Nikolaos Charalampakis, Graciela M. Nogueras-Gonzalez, Elena Elimova, Roopma Wadhwa, Hironori Shiozaki, Yusuke Shimodaira, Mariela A. Blum, Jane Elizabeth Rogers, Jeana Garris, Aurelio Matamoros, Tara L. Sagebiel, Prajnan Das, Jeannelyn Estrella, Brian D. Badgwell, Jaffer A. Ajani; The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, TX.. Signet ring cell (SRC) histology of localized gastric adenocarcinoma (LGAC) to predict response to preoperative chemoradiation. 2015 ASCO Annual Meeting, 2015.
14. Kazuki Sudo, Xuemei Wang, Roopma Wadhwa, Hironori Shiozaki, Wayne Lewis Hofstetter, David C. Rice, Jeffrey H. Lee, Manoop S. Bhutani, Brian Weston, Heath D. Skinner, Ritsuko Komaki, Dipen M. Maru, Mariela A. Blum, Jaffer A. Ajani; The University of Texas MD Anderson eancer Center, Houston, TX. Clinical parameters’ model for predicting distant metastasis (DM) following definitive therapy in patients with localized esophageal and esophagogastric junction (E-EGJ). 2014 Gastrointestinal Cancers Symposium, 2014.
15. Roopma Wadhwa, Xuemei Wang, Julie Izzo, Heath D. Skinner, Jeffrey H. Lee, Manoop S. Bhutani, Brian Weston, William A. Ross, Wayne Lewis Hofstetter, Dipen M. Maru, David C. Rice, Kazuki Sudo, Hironori Shiozaki, Mariela A. Blum, Qiongrong Chen, Jiankang Jin, Shumei Song, Veera Baladandayuthapani, Jaffer A. Ajani; The University of Texas MD Anderson Cancer Center, Houston, TX. Correlation of pretreatment nuclear GLI-1 labeling indices (LIs) with initial SUV (iSUV) in esophageal cancer (EC) patients undergoing trimodality therapy (TMT): A potential pathway to esophageal preservation. 2014 Gatrointestinal Cancers Symposium, 2014.
16. Hironori Shiozaki, Kazuki Sudo, Roopma Wadhwa, Wayne Lewis Hofstetter, Heath D. Skinner, Ritsuko Komaki, Jeffrey H. Lee, Brian Weston, Manoop S. Bhutani, Dipen M. Maru, Mariela A. Blum, Jaffer A. Ajani; The University of Texas MD Anderson Cancer Center, Houston, TX. Distribution and timing of distant metastasis (DM) after definitive therapy for patients with esophageal and esophagastric junction (E-EGJ) cancer. 2014 Gastrointestinal Cancers Symposium, 2014.
17. Elena Elimova, Roopma Wadhwa, Kazuki Sudo, Hironori Shiozaki, Rebecca Slack, Hsiang-Chun Chen, Brian D. Badgwell, Aurelio Matamoros, Jeffrey H. Lee, Brian Weston, Manoop S. Bhutani, Mariela A. Blum, Jeannelyn Estrella, Prajnan Das, Jaffer A. Ajani; MD Anderson Cancer Center, Houston, TX; The University of Texas MD Anderson Cancer Center, Houston, TX. A phase II study of preoperative chemotherapy and chemoradiation for localized gastric and gastroesophageal junction adenocarcinoma (LGCA). 2014 ASCO Annual Meeting, 2014.
18. Taketa T, Correa AM, Suzuki A, Blum MA, Lee JE, Welsh J, Lin SH, Maru D, Erasmus JJ, Bhutani MS, Weston B, Rice DC, Swisher S, Wayne Lewis Hofstetter WL, Ajani JA. Outcome of trimodality-eligible esophagogastric cancer (EC) patients who declined surgery after preoperative chemoradiation. J Clin Oncol 4(6), 2012.
19. Suzuki A, Xiao L, Hayashi Y, Blum MA, Welsh J, Lin SH, Lee JH, Bhutani MS, Weston B, Maru D, Rice DC, Hofstetter WL, Erasmus JJ, Swisher S, Ajani JA. Nomograms for prognostication of patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. J Clin Oncol 4(82), 2012.
20. Lara M Paraskos, Mariela A. Blum, Maricer Escalon, Annapoorna Ferrell, Erin Kobetz, and Joseph Rosenblatt. Defining Outcomes in Hispanic Aggressive Non-Hodgkin Lymphoma Patients. Blood 114(4542), 2009.

Book Chapters

1. Blum M, and Lynch G. Neuroendocrine Tumors. In: Tumor Board Review: Guidelines and Case Reviews in Clinical Oncology, 2011.

Letters to the Editor

1. Ajani JA, Blum MA, Welsh J, Hofstetter WL, Swisher SG. Celebrate or calibrate? We say calibrate. J Clin Oncol 29: 2732; author reply 2732-3, 2011.